Investigating cone outer segment renewal rate

Article

Using SLO/OCT to image the temporal changes of BRS

"It is known from prior in vitro experiences with animals that there is a photoreceptor renewal process, including the formation of new discs at the junction between inner and outer segments and disc shedding followed by phagocytosis at the end of the photoreceptors," she said.1 "However, in vivo observation of this process is still very challenging."

Dr Kroisamer from the department of ophthalmology and the team of Prof. Pircher at the Center for Medical Physics had already studied and published results on bright reflection spots (BRS) found in the outer segments of some cones and assumed that these might be defects within the disc packing.2,3 "So, the aim of our most recent study," she continued, "was to investigate temporal changes of these BRS over time."

To image the cone photoreceptor mosaics of the study group, Dr Kroisamer and colleagues used a custom SLO/OCT imaging device (developed in Prof. Pirchers group).2,4 "We imaged the cone mosaic at about 4° eccentricity from the fovea every 24 hours up to a total of 96 hours," she said. "Our measurements were taken at the same time each day and subjects followed their normal daily routine between measurements."

Once all the measurements had been taken, the team gathered the results and considered those for analysis that had four consecutive images of good quality. "We manually counted all BRS that showed motion in at least three of the four frames and measured the position of each spot at a given time," Dr Kroisamer added.

The team imaged 12 healthy volunteers and was able to obtain images of good quality in five subjects of different ages and with different refractive errors. From these images, it was possible to see BRS progressively moving from the inner segment (IS)–outer segment (OS) junction to the end tips of the cone photoreceptors.

"From the dynamic images, we calculated the motion speed of the BRS," Dr Kroisamer said. "So, in our study we found an OS growth rate that was in good agreement with animal studies and the indirect adaptive optics ophthalmoscope measurements."5

Conclusion

"So in conclusion we were able to observe in vivo the 3D structure of the human cone photoreceptor mosaic over an extended period of time," affirmed Dr Kroisamer. "The measured motion speed of the BRS corresponded well with the estimated cone renewal rate, so this would be the first direct in vivo investigation of the OS renewal process. But of course, further investigations are needed to get a closer insight on this topic."

Special contributorDr Julia-Sophie Kroisamer is a resident at the Department of Ophthalmology and Optometry at the Medical University of Vienna, Austria. She may be reached by Email: julia-sophie.kroisamer@meduniwien.ac.at

Dr Kroisamer has indicated no financial interests in the subject matter.

References

1. Young et al., J. Cell. Biol., 1967;33(1):61–72.

2. Pircher et al., Opt. Express, 2010;18(13):13935–13944.

3. Pircher et al., Biomed. Opt. Express, 2010;2(1):100–112.

4. Pircher et al., Opt. Express, 2007;15(25):16922–16932.

5. Jonnal et al., Opt. Express, 2010;18(5):5257–5270.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.